Drugs / IBI334
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05774873 | Aug 2023 → Mar 2025 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-04-08 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting innoventbio.com ↗
With the aid of B7-H3, IBI334 showed better tumor growth inhibition in vitro and in vivo than EGFR monoclonal antibody and c-met/EGFR bispecific antibody benchmarks. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-04-08 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting innoventbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI334 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05774873 ↗ |
| Action | Inhibit | “In preclinical models, IBI334 outperforms conventional EGFR antibodies by demonstrating superior EGFR occupancy, enhanced ligand-blocking efficacy, accelerated receptor...” PMID 41735305 ↗ Feb 2026 |
| Route | Intravenous | “There are six dose of IBI334 ,QW IV in first cycle and Q2W IV behind the first cycle” NCT05774873 ↗ |
| Target | EGFR | “Leveraging an unbiased functional screen of bispecific antibodies (bsAbs) combining diverse B7-H3 and EGFR binders, we develop IBI334, a EGFR/B7-H3 bsAb exhibiting exceptional...” PMID 41735305 ↗ Feb 2026 |